RNAC — Cartesian Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1453687 ·
Last close
$9.51
Market Cap
$279.42M
52W High
$9.75
52W Low
$5.60
ADV30
338,753
Next earnings
2026-04-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 78,000 | — | -26,499,000 | -39,182,000 | 288,391,000 | 118,641,000 | 436,509,000 |
| Dec 2025 | 947,000 | — | -21,939,000 | -92,576,000 | 296,411,000 | 125,139,000 | 422,651,000 |
| Sep 2025 | 452,000 | — | -21,066,000 | -35,902,000 | 372,675,000 | 143,384,000 | 408,519,000 |
| Jun 2025 | 298,000 | — | -21,811,000 | 15,886,000 | 388,893,000 | 160,324,000 | 391,420,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-72,968,000
Investing CF
$-4,406,000
Financing CF
$15,641,000
CapEx
$-4,406,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.02
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-861,555,000
Inventory
—
Receivables
$261,000
ST Investments
—
EBIT TTM
$-91,315,000
Pretax Income TTM
$-160,967,000
Interest Exp TTM
$0
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,775,000
EBITDA
$-88,897,000
Free Cash Flow
$-46,870,876
Enterprise Value
$172,632,192
Total Cash
$118,641,000
Total Debt
$11,855,000
Shares Out
29,381,514
Trailing EPS
$-5.80
Book Value
$-5.19
ROE
—
ROA
-16.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,797,000 | -86,705,000 | -130,302,000 | 296,411,000 | 422,651,000 | — | -73,941,000 |
| Dec 2024 | 38,913,000 | -36,318,000 | -77,424,000 | 435,023,000 | 441,825,000 | — | -23,674,000 |
| Dec 2023 | 26,004,000 | -85,706,000 | -219,710,000 | 305,050,000 | 745,234,000 | — | -51,161,000 |
| Dec 2022 | 110,777,000 | 14,538,000 | 35,379,000 | 165,886,000 | 72,058,000 | — | -31,631,000 |
TTM Snapshot
Revenues TTM
$65,364,000
NetIncome TTM
$-22,301,000
OpCashFlow TTM
$0
Assets (Latest)
$435,023,000
Forward EPS
$-2.68
Max Pain — expiry 2026-08-21
max pain strike: $7.50 · spot: $8.60 · call oi: 1,238 · put oi: 4
Expected Move to 2026-08-21:
±$5.38
(62.50%) —
implied range
$3.23 –
$13.98
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELDN | Eledon Pharmaceuticals, Inc. | $275.56M | $3.57 | — |
| ELTX | Elicio Therapeutics, Inc. | $283.43M | $14.85 | — |
| NVCT | Nuvectis Pharma, Inc. | $284.09M | $10.71 | — |
| IMRX | Immuneering Corp | $271.08M | $4.19 | — |
| PRLD | Prelude Therapeutics Inc | $291.48M | $4.49 | — |
News headlines (Yahoo Finance, 1h cache)
Cartesian Therapeutics Announces New Employment Inducement Grant
2026-06-12 20:05 · Yahoo
AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
2026-06-10 09:12 · Yahoo
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
2026-06-09 11:00 · Yahoo
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
2026-05-26 11:00 · Yahoo
Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight
2026-05-25 17:00 · Yahoo
Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight
2026-05-18 17:00 · Yahoo
We're Keeping An Eye On Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate
2026-05-17 14:04 · Yahoo
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
2026-05-12 11:00 · Yahoo
Cartesian Therapeutics Announces New Employment Inducement Grants
2026-05-04 11:05 · Yahoo
Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates
2026-04-30 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.